| abstract |
Disclosed is the use of a treatment agent comprising a hydroxytyrosol-rich olive plant extract in the manufacture of a medicament for the treatment of a subject having an inflammatory condition characterized by a detectable clinical symptom or change in a level of a biochemical marker with respect to the normal range of the marker, wherein the marker or the clinical symptom is selected from the group consisting of: (i) the symptoms and markers in joint pain and swelling in the case of joint inflammation; (ii) elevated levels of C-reactive protein in the case of coronary inflammation; (iii) respiratory distress in the case of bronchial inflammation; and (iv) elevated CSF levels of isoprostanes or functional or psychofunctional indicators in the case of neuro-inflammation. |